Viatris Inc is a healthcare company. The company’s portfolio consists of approved molecules including generics, complex generics, and biosimilars. Viatris operates its business through four segments – Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment includes operations essentially in North America and Europe. It offers products including Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, the EpiPen auto-injector, Hulio, Fraxiparine, and Yupelri. The Greater China segment consists of its operations in mainland China, Taiwan and Hong Kong. The major products in this segment include Lipitor, Norvasc, and Viagra. The JANZ segment covers operations in Japan, Australia, and New Zealand. This segment offers products such as AMITIZA, Lipacreon, Lyrica, Norvasc, and Effexor. The Emerging Markets segment includes the company’s presence in over 125 countries with developing markets and emerging economies comprising Asia, Africa, Eastern Europe, Latin America, and the Middle East and its antiretroviral (ARV) franchise. In this segment, the company offers Lipitor, Lyrica, Norvasc, Celebrex, and ARVs. The Emerging Markets segment also provides Remdesivir and various biosimilars. Its research, development and clinical platform, including regulatory activities, strive to capture new product opportunities in all its categories and markets and to assess opportunities to widen the reach of its existing product range. Viatris’s product pipeline includes dosage forms such as oral solid dosage forms, transdermals, injectables, inhalation, and other delivery systems.